MDT

100.01

+0.25%↑

146.96

+0.77%↑

VEEV

244.4

+2.32%↑

HQY

97.41

-0.3%↓

PHR.US

16.95

-3.09%↓

MDT

100.01

+0.25%↑

146.96

+0.77%↑

VEEV

244.4

+2.32%↑

HQY

97.41

-0.3%↓

PHR.US

16.95

-3.09%↓

MDT

100.01

+0.25%↑

146.96

+0.77%↑

VEEV

244.4

+2.32%↑

HQY

97.41

-0.3%↓

PHR.US

16.95

-3.09%↓

MDT

100.01

+0.25%↑

146.96

+0.77%↑

VEEV

244.4

+2.32%↑

HQY

97.41

-0.3%↓

PHR.US

16.95

-3.09%↓

MDT

100.01

+0.25%↑

146.96

+0.77%↑

VEEV

244.4

+2.32%↑

HQY

97.41

-0.3%↓

PHR.US

16.95

-3.09%↓

Home・Akciju saraksts・CytomX Therapeutics Inc

CytomX Therapeutics Inc

Atvērts

SektorsVeselības aprūpe

4.22 -0.47

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.12

Max

4.4

Galvenie mērījumi
By Trading Economics
Ienākumi	-14M -14M
Pārdošana	-13M 6M
P/E Sektora vidējais	13.733 87.826
Peļņas marža	-238.621
Darbinieki	119
EBITDA	-13M -14M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+65.12% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	50M 698M
Iepriekšējā atvēršanas cena	4.69
Iepriekšējā slēgšanas cena	4.22

Ziņu noskaņojums

By Acuity

50%

166 / 372 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

0.7658 / N/A Atbalsts un pretestība

CytomX Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 7. janv. 23:11 UTC

Peļņas

Samsung Electronics Expects Record Fourth-Quarter Profit Beat

2026. g. 7. janv. 22:55 UTC

Galvenie tirgus virzītāji

Defense Stocks Rebound After Trump Says He Wants $1.5 Trillion Military Budget in 2027

2026. g. 7. janv. 21:39 UTC

Galvenie tirgus virzītāji

Raytheon Down Following Trump Post Criticizing Company

2026. g. 7. janv. 20:13 UTC

Galvenie tirgus virzītāji

AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition

2026. g. 7. janv. 20:03 UTC

Galvenie tirgus virzītāji

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Executive Pay

2026. g. 7. janv. 23:46 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 7. janv. 23:46 UTC

Tirgus saruna

Nikkei May Decline as China-Japan Tensions Linger -- Market Talk

2026. g. 7. janv. 23:42 UTC

Iegādes, apvienošanās, pārņemšana

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 5th Update

2026. g. 7. janv. 23:34 UTC

Tirgus saruna

Gold Edges Higher Amid Lingering Geopolitical Risks -- Market Talk

2026. g. 7. janv. 23:29 UTC

Iegādes, apvienošanās, pārņemšana

Constellation Closes Deal for Calpine, Creating Biggest Electricity Generator -- Barrons.com

2026. g. 7. janv. 22:48 UTC

Tirgus saruna

Infratil's Discount to Net Asset Value Too Good to Ignore -- Market Talk

2026. g. 7. janv. 22:46 UTC

Peļņas

Samsung Electronics Estimates 2025 Rev KRW332.770T Vs KRW300.870T >005930.SE

2026. g. 7. janv. 22:45 UTC

Peļņas

Samsung Electronics Estimates 2025 Oper Pft KRW43.530T Vs KRW32.730T >005930.SE

2026. g. 7. janv. 22:43 UTC

Iegādes, apvienošanās, pārņemšana

Revolution Medicines Draws Takeover Interest -- 2nd Update

2026. g. 7. janv. 22:42 UTC

Peļņas

Samsung Electronics 4Q Oper Pft Estimate Beat FactSet-Compiled Consensus Forecast

2026. g. 7. janv. 22:41 UTC

Peļņas

Samsung Electronics Sees 4Q Oper Pft KRW20.000T Vs KRW6.490T >005930.SE

2026. g. 7. janv. 22:41 UTC

Peļņas

Samsung Electronics Sees 4Q Rev KRW93.000T Vs KRW75.790T >005930.SE

2026. g. 7. janv. 22:40 UTC

Galvenie tirgus virzītāji

Defense Stocks Rebound After Trump Says He Wants $1.5T Military Budget in 2027

2026. g. 7. janv. 22:31 UTC

Tirgus saruna

Macro Tailwinds Strengthen for Chalice Mining -- Market Talk

2026. g. 7. janv. 22:22 UTC

Tirgus saruna

Northern Star's Run of Disruptions Increasingly a Concern -- Market Talk

2026. g. 7. janv. 22:01 UTC

Tirgus saruna

Valuations of New Zealand Property Stocks Supportive -- Market Talk

2026. g. 7. janv. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 7. janv. 21:46 UTC

Tirgus saruna

Northern Star's Revised Guidance Looks Achievable -- Market Talk

2026. g. 7. janv. 21:22 UTC

Iegādes, apvienošanās, pārņemšana

Eli Lilly to Buy Ventyx Biosciences for $14 a Share >LLY VTYX

2026. g. 7. janv. 21:18 UTC

Iegādes, apvienošanās, pārņemšana

Lilly To Acquire Ventyx Biosciences To Advance Oral Therapies Targeting Inflammatory-mediated Diseases >LLY VTYX

2026. g. 7. janv. 21:05 UTC

Iegādes, apvienošanās, pārņemšana

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 4th Update

2026. g. 7. janv. 20:29 UTC

Iegādes, apvienošanās, pārņemšana

AbbVie Near Deal for Revolution Medicines -- Update

2026. g. 7. janv. 20:27 UTC

Tirgus saruna

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

2026. g. 7. janv. 19:58 UTC

Tirgus saruna

Oil Falls As U.S. to Receive Sanctioned Venezuelan Crude -- Market Talk

2026. g. 7. janv. 19:48 UTC

Galvenie tirgus virzītāji

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Exec Pay

Salīdzinājums

Cenas izmaiņa

CytomX Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

65.12% augšup

Prognoze 12 mēnešiem

Vidējais 7.1 USD 65.12%

Augstākais 10 USD

Zemākais 6 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi CytomX Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam CytomX Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

0.7658 / N/AAtbalsts un pretestība

Bullish events outweigh bearish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Noskaņojums

By Acuity

166 / 372 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.